VistaGen Therapeutics Inc

-0.10 (-3.60%)
Earnings Announcements

Vistagen Therapeutics Inc QTRLY Total Revenue $1.1 Million

Published: 06/29/2021 20:46 GMT
VistaGen Therapeutics Inc (VTGN) - Vistagen Therapeutics Inc Qtrly Total Revenue $1.1 Million.
Vistagen Therapeutics Inc Qtrly Loss per Share $0.49.
Vistagen - Palisade-1 Phase 3 Trial Underway to Evaluate Ph94b for Rapid-onset Acute Treatment of Anxiety in Adults With Social Anxiety Disorder.
Vistagen - at March 31, 2021, Co Had Cash & Cash Equivalents of About $103.1 Million.
Revenue is expected to be $0.39 Million
Adjusted EPS is expected to be -$0.05

Next Quarter Revenue Guidance is expected to be $0.39 Million
Next Quarter EPS Guidance is expected to be -$0.07

More details on our Analysts Page.